Drug intelligence / Profile preview

honey based syrup

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A natural product formulation, "honey based syrup" is being investigated for its potential to affect blood parameters in breast cancer patients undergoing chemotherapy. Honey, a primary component, is known for its antioxidant, anti-inflammatory, and potential anticancer properties. The specific formulation in the clinical trial (NCT04426435) may also contain saffron and rose water.

Targets

AKT (RAC-alpha serine/threonine-protein kinase)mTOR (Mammalian target of rapamycin kinase)AMPK (Adenosine monophosphate–activated protein kinase)STAT3 (Signal Transducer and Activator of Transcription 3)INSR (Insulin receptor)

Beyond the preview

Go deeper on honey based syrup.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on honey based syrup.

Explore the full profile